These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33647005)

  • 1. Osilodrostat (Isturisa) for Cushing's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.
    Simões Corrêa Galendi J; Correa Neto ANS; Demetres M; Boguszewski CL; Nogueira VDSN
    Front Endocrinol (Lausanne); 2021; 12():732240. PubMed ID: 34603209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
    Paton DP
    Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prospects for drug treatment in Cushing disease.
    Barahona Constanzo MJ; del Pozo Picó C
    Endocrinol Nutr; 2012 Dec; 59(10):599-605. PubMed ID: 23036936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of Cushing's disease: where are we now?
    Alexandraki KI; Grossman AB
    Front Horm Res; 2010; 38():165-173. PubMed ID: 20616508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How best to monitor the specific side effects of medical treatments of Cushing's disease.
    Castinetti F
    Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101718. PubMed ID: 36435719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
    Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
    Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence.
    Chabre O; Muller M; Cristante J; Cracowski JL; Gay E
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):384-385. PubMed ID: 35597254
    [No Abstract]   [Full Text] [Related]  

  • 15. Next generation medical therapy for Cushing's syndrome--can we measure a benefit?
    Trainer PJ
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1157-60. PubMed ID: 24702012
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.
    Pivonello R; Ferrigno R; De Martino MC; Simeoli C; Di Paola N; Pivonello C; Barba L; Negri M; De Angelis C; Colao A
    Front Endocrinol (Lausanne); 2020; 11():648. PubMed ID: 33363514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 infection in a patient with Cushing's disease on osilodrostat treatment.
    Bogusławska A; Minasyan M; Hubalewska-Dydejczyk A; Gilis-Januszewska A
    Endokrynol Pol; 2023; 74(3):342-343. PubMed ID: 37335068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osilodrostat for the treatment of Cushing's disease.
    Rasool S; Skinner BW
    Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.